Alexion Pharmaceuticals Inc
AstraZeneca to Acquire Alexion for $39 Billion, Stock Down
Bridgewater: What Are Ray Dalio’s Top Investing Ideas?
Founded by Ray Dalio, Bridgewater Associates’ top sell in the third quarter was the iShares MSCI Emerging Markets ETF (EEM).
Amgen’s Alexion Acquisition: Does It Make Sense?
On August 21, Spanish website Intereconomia reported that Amgen would be announcing its acquisition of Alexion Pharmaceuticals in the next few days.
Why Neurocrine Biosciences Stock Is Plummeting Today
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
How Analysts View Alexion Stock
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.
Analyzing Alexion Pharmaceuticals’ Product Performance
Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.
Alexion Pharmaceuticals: What to Expect from Its Q3 Earnings
Alexion Pharmaceuticals (ALXN) is scheduled to report its third-quarter earnings on October 24.
A Look at Sarepta Therapeutics’ Stock Performance
After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.
Analyzing Sarepta’s Product Pipeline
Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.
How Alexion Pharmaceuticals Is Positioned in October
In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.
A Look at Portola Pharmaceuticals’ Financial Performance
Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018.
Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
Alexion Pharmaceuticals to Acquire Syntimmune
In this series, we’ll look at how companies in the rare disease space have been performing, as well as recent news.
Alexion’s Soliris Continues to See Growth
Alexion Pharmaceuticals’ (ALXN) products on the market include Soliris, Strensiq, and Kanuma.
How BioMarin Pharmaceutical Is Positioned Financially in August
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.
How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.
What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.
Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals
Jazz Pharmaceuticals anticipates net revenues to be in the range of $1.88 million to $1.93 million in fiscal 2018.
How Did Jazz Pharmaceuticals Perform in the Second Quarter?
Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.
Analysts Are Bullish on Sarepta Therapeutics
Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.
What Alnylam’s Bottom Line Is Expected to Look Like in Q2 2018
Alnylam Pharmaceuticals’ (ALNY) selling, general, and administrative expenses are expected to rise 73.46%.
How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?
BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.
What Gilead Sciences’ Bottom Line Is Expected to Look Like in Q2
Gilead Sciences’ (GILD) research and development expenses are expected to increase 8.78%, from $812 million in Q2 2017 to $883.27 million in Q2 2018.
Why Most Analysts Recommend a ‘Buy’ for Alexion Stock
Analysts expect Alexion Pharmaceuticals’ (ALXN) interest expense to decline by 5.32% from $24 million in Q2 2017 to $22.72 million in Q2 2018.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
Vivus Stock Rose 60% Last Week
Vivus stock rose 60% between May 11 and May 18.
Alexion Delivered a Solid Financial Performance in Q1 2018
Alexion Pharmaceuticals (ALXN) generated total revenue of $931 million in the first quarter of 2018.
Exploring the Promising Research Pipeline of Alexion Therapeutics
Alexion plans to begin a Phase 3 study of a subcutaneous formulation of ALXN1210 in late 2018.
Analyzing Alexion’s Acquisition of Wilson Therapeutics
In April, Alexion announced a tender offer to acquire Sweden-based Wilson Therapeutics.
How Much Upside Do Analysts See in Alexion Stock?
Of the 19 analysts covering Alexion Pharmaceuticals in May, 18 have given the stock “buy” or higher ratings.
Recent Developments, Recommendations for JAZZ in May
In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application to the FDA for the label expansion of Xyrem.
How Did Jazz Pharmaceuticals Perform in 1Q18?
In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17.
Alexion: Analysts Raise Their Target Prices
As of April 12, 2018, 18 analysts gave a “buy” or “strong buy” recommendation on Alexion stock, while one analyst gave a “hold” recommendation.
WTX101: A Superior Treatment for Wilson Disease
WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.
Wilson Disease: A Market Opportunity for Alexion
Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.
Strategic Rationale behind Alexion’s Acquisition
Acquiring Wilson Therapeutics is expected to be a strategic fit for Alexion. Alexion is focused on developing life-transforming rare disease therapies.
Alexion to Acquire Wilson Therapeutics for $855 Million
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders.
Alexion Pharmaceuticals: Strensiq and Kanuma in 2017
In 4Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of $95.6 million, which reflected ~35% growth on a YoY (year-over-year) basis.
Alexion Pharmaceuticals in 4Q17 and Fiscal 2017
In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.
Inside Pfizer’s Rare Disease Segment Performance in 2017
In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.
How Biogen’s Spinraza Is Positioned for 2018
In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.
A Look at Ionis Pharmaceuticals’ January 2018 Valuation
On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.
How’s Incyte’s Valuation in January 2018?
Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.
Thermo Fisher Scientific’s Deepening Ties with Sema4
Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.
Analyst Recommendations for Alexion in December 2017
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Confirmatory Studies May Expand Uptake of Exondys 51
Demand trends Sarepta Therapeutics (SRPT) reported that by the end of 3Q17, all Tier 1 and Tier 2 sites, which will be treating around 75% of DMD (Duchenne muscular dystrophy) patients with mutations amenable to exon-51 skipping, had submitted start forms for Exondys 51 (eteplirsen). The company has also witnessed an increase in start forms submitted […]
Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals
On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.
Patisiran Expected to Become Key Growth Driver for Alnylam
Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.
Spinraza Continues to See Improvement in Sales Metrics in 2017
Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza has been witnessing improvement in infrastructure and payer access for spinal muscular atrophy (or SMA) patients in the US in 2017.
Spinraza Has Emerged as Key Growth Driver for Ionis in 2017
In 1H17, Ionis Pharmaceuticals (IONS) recorded revenues of about $27.6 million related to royalty income received from Biogen from Spinraza sales.
Analysts’ Recommendations for Biogen in October 2017
Recent developments In October 2017, Biogen (BIIB) and Eisai expanded their existing agreement on the joint development and commercialization of Alzheimer’s disease therapies under investigation. According to the terms of the agreement, Eisai has the option to co-develop and co-commercialize Biogen’s aducanumab for the treatment of Alzheimer’s disease patients. The present expansion of the agreement […]
Gauging Alexion’s 2018 Growth with Soliris
In 2Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of ~$814 million, which represented a ~16% YoY rise and a ~4% QoQ rise.
How Did BioMarin Pharmaceuticals’ Drugs Perform in 1H17?
In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis.
How Is Jazz’s Defitelio Positioned after 2Q17?
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver
In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
How Are Orkambi and Kalydeco Positioned after 2Q17?
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.
How Pfizer’s Rare Disease Franchise Stands after 2Q17
In 1H17, BeneFix generated revenues of ~$302 million, which reflected an ~18% decline on a YoY basis.
Analysts’ Recommendations for Pfizer in August 2017
Of the 22 analysts covering Pfizer (PFE) in August 2017, one analyst recommended a “strong buy” and ten analysts recommended a “buy.” On August 26, Pfizer had a consensus 12-month target price of $37.45 for a 12.7% return on investment.
New Patients and Alexion Pharmaceuticals’ Metabolic Franchise
Alexion Pharmaceuticals (ALXN) has reiterated its 2017 revenue guidance of $375.0 million–$400.0 million for its metabolic franchise.
Alexion Pharmaceuticals Expects Robust Revenue for Soliris
Alexion Pharmaceuticals (ALXN) raised its 2017 revenue projections for Soliris from $3.025 billion–$3.1 billion to $3.075 billion–$3.125 billion.
Alexion Pharmaceuticals Raised 2017 Earnings Guidance
Alexion Pharmaceuticals (ALXN) raised its 2017 non-GAAP guidance from the previously estimated $5.10–$5.30 to $5.40–$5.55.
Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
Bioverativ Expected to Report Healthy Profit Margins in 2017
Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.
Bioverativ Expected to Report Robust Revenue Growth in 2017
In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.
Bioverativ–True North Therapeutics: Stronger Research Pipeline
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).
Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
What Analysts Recommend for BioMarin Pharmaceuticals
A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”
BioMarin Expects These Drugs to Generate Steady Revenues
In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.
What to Expect from BioMarin Pharmaceuticals in 2017
In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).
How Incyte’s Valuation Has Changed since 1Q17 Results
Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
Analysts’ Views on Alexion Pharmaceuticals and Its Peers
Of the 21 analysts analyzing Alexion Pharmaceuticals, six analysts recommended a “strong buy” and 11 analysts recommended a “buy.”
Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017
In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.
Soliris Is Expected to Continue Generating High Revenue
In 1Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenue of ~$783 million, which is ~18% YoY (year-over-year) growth.
Healthcare Sector Overview: Week of May 22–26, 2017
Through May 26, 2017, 83% of healthcare stocks have delivered earnings above analysts’ estimates. About 16% of healthcare stocks have missed analysts’ estimates, while 2% reported earnings in line with analysts’ estimates.
ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue
Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.
Alexion Pharmaceuticals Projects Robust 2017 Revenue Performance
Alexion Pharmaceuticals (ALXN) expects to report revenue in the range of $3.4 billion–$3.5 billion in 2017.
Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17
To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.
Biogen Has Developed a Robust Access Strategy for Spinraza
In 1Q17, Biogen’s (BIIB) Spinraza earned revenues of $47.0 million, of which $46.0 million were from the US market.
Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17
Spinraza, Biogen’s (BIIB) SMA (spinal muscular atrophy) therapy, was approved by the FDA (U.S. Food and Drug Administration) on December 23, 2016.
Valeant’s Net Profit Margins Expected to Narrow in 2017
Net profit margins Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, the company will also have to bear $1.9 billion in cash interest in 2017, which includes $100 million in amortized deferred financing costs. Wall Street analysts have projected that […]
Valeant Pharmaceuticals Expects Lower Revenue in 2017
Decline in revenue In fiscal 2017, Valeant Pharmaceuticals (VRX) expects to report revenue of $8.9 billion–$9.1 billion. This projection is based on foreign exchange rates in February 2017. It also includes revenue expected from sales of the company’s skincare products, as Valeant does not expect the divestiture transactions to be completed before the end of 2017. Wall […]
Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.
How Do Analysts View Alnylam Pharmaceuticals in 2017?
Of the 15 analysts covering Alnylam Pharmaceuticals (ALNY) in February 2017, two rated the company as a “strong buy,” six rated it as a “buy,” and seven rated ALNY as a “hold.”
What Alexion Expects from Its Metabolic Disease Drugs in 2017
For fiscal 2017, Alexion (ALXN) has projected its metabolic disease franchise to earn revenues in the range of $375 million–$400 million.
Alexion’s Soliris: Gauging Patient Demand
For fiscal 2017, Alexion Pharmaceuticals (ALXN) expects to Soliris’ sales to be in the range of $3.02 billion–$3.10 billion.
Inside Alexion’s Latest Analyst Recommendations
In 2016, Alexion (ALXN) reported revenues of nearly $3.1 billion, which represents a YoY growth of ~18%.
Vertex Expects Modest Revenue Growth in This
Vertex (VRTX) has projected Orkambi’s revenues to fall in the range of $1.0 billion–$1.3 billion in 2017.
Strensiq Boosted Alexion Pharmaceuticals’ Revenues in 2016
On October 23, 2015, Alexion Pharmaceuticals’ Strensiq was approved by the FDA as therapy for perinatal, infantile and juvenile-onset HPP patients.
Will Soliris Drive Alexion Pharmaceuticals’ Revenues in 2017?
In 2016, Alexion Pharmaceuticals (ALXN) continued to witness solid uptake for Soliris. It witnessed strong demand in the AHUS segment around the world.
Vertex Has Adopted Multiple Approaches to Treat Cystic Fibrosis
Vertex Pharmaceuticals (VRTX) is aiming to increase the number of patients eligible to be treated with its drugs to include the entire CF patient population.
Why United Therapeutics Expects Strong Revenue Growth
United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.
What Are Analysts Saying about Horizon Pharma?
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug
Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.
How Did Horizon Pharma Perform in 3Q16?
In 3Q16, Horizon Pharma’s (HZNP) net sales on a GAAP basis fell to $208.7 million. Non-GAAP net sales were $273.7 million.
Horizon Pharma’s Steep Fall in December: What Happened?
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.
How Could Gilead Sciences Restore Its Growth?
With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.
What Do Analysts Say about Regeneron after 3Q16 Earnings?
Regeneron Pharmaceuticals (REGN) released earnings for 3Q16 on November 4, 2016.
BioMarin’s Disappointing 3Q16 Earnings
BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.